Endometriosis, a high-risk obstetric condition: pathophysiology of the maternal-placenta axis

Review OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by qwen3.7-flash, 2026-11-22 ⓘ

This review examines how endometriosis, particularly adenomyosis and deep infiltrating disease, causes placental defects through inflammation and vascular dysfunction, leading to adverse obstetric outcomes like preeclampsia and fetal growth restriction.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis, affecting 190 million reproductive-age women worldwide, emerges as a systemic inflammatory disorder that has been associated with an increased risk of adverse obstetric outcomes. Defective deep placentation has been proposed as a potential mechanism linking endometriosis to these complications, although direct causal evidence remains limited. First-trimester progesterone resistance and decidual senescence are associated with an increased risk of miscarriage, whereas altered decidual natural killer cells and macrophages with a pro-inflammatory phenotype have been implicated in impaired spiral artery remodeling; although most supporting data are indirect or derived from related conditions. These mechanisms may contribute to placenta prævia, preeclampsia and fetal growth restriction in later gestation. Phenotypic severity particularly adenomyosis and deep infiltrating disease exacerbates junctional zone fibrosis and cytokine dysregulation (interleukin-6, tumor necrosis factor-α) compounded by endothelial dysfunction and prothrombotic states. Potential precision-obstetrics approaches include preconception phenotyping, early uterine artery Doppler at 11-14 weeks' gestation, intensified fetal biometry and low-dose aspirin (75-150 mg daily before 16 weeks); however, the clinical benefit of these strategies specifically in endometriosis requires further evaluation in prospective studies. Reframing endometriosis as a potential vascular risk equivalent opens perspectives for prospective trials on immune-modulatory therapies and personalized biomarkers, potentially improving maternal-fetal outcomes in this high-burden population.

My notes (saved in your browser only)

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (86)

Source provenance

openalex
last seen: 2026-11-21T06:07:56.064915+00:00
pubmed
last seen: 2026-11-21T06:09:43.705417+00:00
License: CC0 · commercial use OK